The Lung HIV Microbiome Project (LHMP) - Catalog

  • Name

    The Lung HIV Microbiome Project (LHMP)

  • Accession Number

    HLB01951515a

  • Acronym

    LHMP

  • Related studies
  • BSI Study IDs

    LHMP

  • Is public use dataset

    False

  • Keywords
  • Ingestion Status
    ---------
  • Has Study Datasets

    False

  • Has Specimens

    True

  • Specimen ID Type
    Coded
  • Study Website

    https://biostatcenter.gwu.edu/?pkey=54

  • The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

    False

  • Clinical Trial URLs
    N/A
  • Study type
    Epidemiology Study
  • Collection Type
    Open BioLINCC Study
  • Cohort type
    Adult
  • Interventions
  • Study Open Date (Data)

    None

  • Study Open Date (Specimens)

    2015-10-12

  • Date materials available

    2015-10-08

  • Last updated

    None

  • Study period

    October 2009 – November 2015

  • Study Contacts
  • NHLBI Division

    DLD

  • Classification
    Lung
  • HIV study classification
    HIV
  • COVID study classification
    non-COVID
  • Pre-Website # of Specimens Shipped

    0

  • # of Returned Specimens

    90

  • Primary Publication URLs
    N/A
  • Conditions
    HIV-1
    Lung Diseases
  • Objectives

    To characterize the microbiome of the lung and respiratory tract, and enhance understanding of the role of the lung microbiome in preserving health or causing disease and in the divergent effects observed in HIV-infected versus uninfected individuals.

  • Background

    The respiratory tract is constantly exposed to the external environment and serves as the portal of entry for many microbes. The characteristics and mix of organisms populating the respiratory tract, coupled with the state of local respiratory defenses are key factors in determining whether a person remains healthy or develops acute, chronic, or latent infection. Inflammation in the airways and lungs and how it progresses or is resolved affects not only local immune mediators and primary gas exchange functions, but may also have consequences for the whole immune system and the progression of diseases in other organs.


    HIV-infected individuals are at high risk of developing pneumonias caused by pathogenic and opportunistic microorganisms. These respiratory infections frequently cause morbidity, are often life threatening, and may increase the rate of replication of HIV, accelerating the course of the disease. HIV-infected individuals experience a decrease in lung function following pneumonias which are not observed in normal, HIV-uninfected populations. Furthermore, lung infections and microbial colonizations are suspected in the etiology of HIV-associated emphysema and pulmonary hypertension. An increasingly important issue is that lung infections may play a role in inducing the immune reconstitution syndrome seen in some HIV-infected patients following initiation of multi-drug antiretroviral regimens.


    Therefore, knowledge of the lung microbiome in healthy and diseased states may lead to the identification of predictors of disease progression and therapeutic targets for translation into better preventive and treatment strategies. The LHMP was developed as a cooperative network responsible for carrying out both joint protocols and integrating independent protocols that benefit from increased sample size. This effort was meant to provide initial data to develop further hypotheses addressing differences between HIV-infected and HIV-uninfected individuals.

  • Participants

    Eligible subjects included HIV positive and HIV negative adults. Participant eligibility for the LHMP was confirmed by each center according to the parameters of their individual protocols, which may also define additional inclusion or exclusion criteria.

  • Design

    The LHMP brought the distinct efforts of six clinical centers together under a single infrastructure, creating a network that combined the expertise accumulated across the range of involved disciplines in a focused and concentrated collaboration. Since multiple studies were involved in the project, the research design of each study will vary with the objective of that study. All data and samples were collected during a baseline assessment for LHMP.

  • Conclusions
  • Disease classification
  • Publications
  • Mat types
    Bronchial Lavage
    Oral Wash (Saline)
    Peripheral Blood Mononuclear Cells
    Plasma
  • Network

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. PDF Section 3.0 of the BioLINCC Handbook describes the components of the review process.

  • Material Types

    Last Modified: Oct. 26, 2018, 10:54 a.m.
  • General Freeze/Thaw Status
  • Visits (Vials)
    10/26/2018
     
      Plasma PBMC Bronchial Lavage Oral Wash Total
    1 Visit Per Subject 556 52 1199 242 2049
     

    Last Modified: Oct. 26, 2018, 10:54 a.m.
  • Visits (Subjects)
    10/26/2018
     
      Plasma
    Total number of subjects Average volume (ml) per subject
    1 Visit Per Subject 140 1.22
     
      Bronchial Lavage
    Total number of subjects Average volume (ml) per subject
    1 Visit Per Subject 182 14.17
     
      Oral Wash
    Total number of subjects Average volume (ml) per subject
    1 Visit Per Subject 142 1.78
     
      PBMC
    Total number of subjects Average vials per subject
    1 Visit Per Subject 26.00 2.00
     

    Last Modified: Oct. 26, 2018, 10:54 a.m.